Alzheimer's test reveals severity

A blood biomarker can reveal the severity of Alzheimer's disease, research suggests.

A team from Erasmus Medical Centre in Rotterdam, the Netherlands, found levels of the protein clusterin were linked to the prevalence and severity of Alzheimer's disease. But it found no link with the development of Alzheimer's, suggesting it is not a useful target for detecting risk.

Researchers analysed baseline plasma levels of clusterin in 60 patients with Alzheimer's disease and a control group of 926 patients. These patients, and a further 156 patients diagnosed with Alzheimer's during the follow-up, were measured again after 7.2 years.

The likelihood of developing Alzheimer's disease increased by 63 per cent for each standard deviation increase in plasma clusterin level.

Visit JAMA for more Alzheimer's articles

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus